What Will Happen to Apricus Biosciences Inc (NASDAQ:APRI) Next? The Stock Has Decline in Shorts

June 18, 2018 - By Stephen Andrade

The stock of Apricus Biosciences Inc (NASDAQ:APRI) registered a decrease of 17.02% in short interest. APRI’s total short interest was 1.05 million shares in June as published by FINRA. Its down 17.02% from 1.26M shares, reported previously. With 1.10 million shares average volume, it will take short sellers 1 days to cover their APRI’s short positions. The short interest to Apricus Biosciences Inc’s float is 9.17%.

The stock increased 1.48% or $0.0054 during the last trading session, reaching $0.3691. About 204,737 shares traded. Apricus Biosciences, Inc. (NASDAQ:APRI) has declined 69.41% since June 18, 2017 and is downtrending. It has underperformed by 81.98% the S&P500.

Apricus Biosciences, Inc., a biopharmaceutical company, focuses on the development and commercialization of product candidates in the areas of urology and rheumatology. The company has market cap of $8.65 million. The Company’s lead product is Vitaros, a topically-applied cream formulation of alprostadil used for the treatment of erectile dysfunction. It currently has negative earnings. The firm also engages in developing RayVa, which is in Phase 2 development for the treatment of RaynaudÂ’s Phenomenon associated with scleroderma; and Fispemifene, a tissue-specific selective estrogen receptor modulator for the treatment of secondary hypogonadism, chronic prostatitis, and lower urinary tract symptoms in men.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: